Market capitalization | $129.66m |
Enterprise Value | $-47.21m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.61 |
EV/Sales (TTM) EV/Sales | -0.71 |
P/S ratio (TTM) P/S ratio | 1.95 |
P/B ratio (TTM) P/B ratio | 0.74 |
Revenue growth (TTM) Revenue growth | 18.19% |
Revenue (TTM) Revenue | $66.52m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
7 Analysts have issued a Repare Therapeutics Inc forecast:
7 Analysts have issued a Repare Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 67 67 |
18%
18%
|
|
Gross Profit | 65 65 |
24%
24%
|
|
EBITDA | -89 -89 |
10%
10%
|
EBIT (Operating Income) EBIT | -91 -91 |
12%
12%
|
Net Profit | -84 -84 |
14%
14%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using synthetic lethality approach in Canada. It provides SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The company's lead product candidate is RP-3500 a potent and selective oral small molecule inhibitor of ATR for the treatment of tumors with mutations in ataxia-telangiectasia mutated kinase. It also develops CCNE1-SL, a proprietary drug discovery program for tumors with amplification of CCNE1; and polymerase theta inhibitor. The company was founded in 2016 and is headquartered in St. Laurent, Canada.
Head office | Canada |
CEO | Lloyd Segal |
Employees | 179 |
Founded | 2016 |
Website | www.reparerx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.